Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

Inclusion criteria

• Subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined by:

• Investigator's Global Assessment (IGA) score of 3 (Moderate) OR 4 (Severe ); and
• A minimum of 25-100 inflammatory lesions (papules and pustules); and
• A minimum of 30-150 non-inflammatory lesions (open and closed comedones) in total (excluding the nose); and
• No more than two acne nodules (≥ 1 cm),
• Subject with skin phototype IV to VI on Fitzpatrick skin phototype scale,
• Subjects from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American,

Exclusion criteria

• Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, acne requiring systemic treatment,
• Subject with history of lupus, atopic dermatitis, perioral dermatitis, dermatomyositis, rosacea
• Female subject who is pregnant, lactating or planning a pregnancy during the trial,
• Subjects having received at least one of the following topical treatments on the treated area: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone, hydroxyacids, Zinc containing treatments, antiseptics, other anti-inflammatory products or other acne treatments (2 weeks); Retinoids (4 weeks); Cosmetic/aesthetic procedures on the face (1 week); Wax epilation (2 weeks); Photodynamic therapy (6 weeks); Laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne (3 months).
• Subjects having received at least one of the following systemic treatments: Corticosteroids, tetracyclines, other antibiotics (except penicillin) (1 month); Oral retinoids/isotretinoin/ anti-androgens / Cyproterone acetate / Chlormadinone acetate (6 months); Spironolactone/ Drospirenone (3 months); Immunomodulators (3 months) and Oral contraceptives/ oral dapsone for acne(1 month).